$31.00
+0.64 (+2.11%)
Open$30.29
Previous Close$30.36
Day High$31.55
Day Low$29.89
52W High$38.33
52W Low$2.45
Volume—
Avg Volume369.4K
Market Cap1.73B
P/E Ratio—
EPS$-12.01
SectorBiotechnology
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.65M | 7.80M | 6.88M |
| Net Income | -2,097,514 | -1,645,262 | -1,540,052 |
| Profit Margin | -27.4% | -21.1% | -22.4% |
| EBITDA | -2,154,773 | -2,236,853 | -1,912,817 |
| Free Cash Flow | -1,120,093 | -988,846 | -1,121,747 |
| Rev Growth | +8.4% | +22.8% | +24.7% |
| Debt/Equity | 0.85 | 0.67 | 0.79 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |